Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Takeda Pharma raises profit forecast as it focuses on core drug businesses

Published 2020-07-31, 02:39 a/m
© Reuters. Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co (T:4502) on Friday raised its full-year profit forecast as the company refocuses on its core prescription drug businesses following its $59 billion takeover of Shire Plc (LON:SHP) last year.

Japan's largest drugmaker by revenue expects operating profit of 395 billion yen ($3.78 billion) in the year through March 2021, it said on Friday in reporting quarterly earnings.

The revision to its forecast was mainly due to one-time items, Takeda said. It compares with a previous forecast of 355 billion yen in operating profit and a consensus of 382.5 billion yen in a Refinitiv poll of 13 analysts.

Takeda announced earlier this year a pause in the start of new drug trials except for its plasma-derived COVID-19 therapy.

It has formed an alliance of 10 global plasma companies to develop a shared therapy that uses immune cells from the blood of recovered coronavirus patients.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.